hot news

On August 31, the China Reproductive Health Industry Association issued an approval notice for the application by Shaanxi 38fule Technology Group to establish China's first reproductive health industry stem cell research and achievement transformation base. This signifies the establishment of the country's inaugural base for stem cell research and the transformation of achievements in the reproductive health industry at the 38fule Group. Shaanxi 38fule Technology Group is also a Vice-Chairman Unit of the Shaanxi International Medical Exchange Promotion Association

Reproductive health is crucial to human development. Currently, China's fertility rate has declined, with infertility increasingly becoming a significant social and public health issue. In this context, reproductive health has emerged as one of the important subjects in life sciences. Therefore, in the approval document, the China Reproductive Health Industry Association stated, "To promote deep cooperation of high-quality resources, encourage the broad application of regenerative medicine research findings in the field of reproductive health, achieve high-quality development of China's reproductive health industry, and support the construction of a 'Healthy China,' our association supports the establishment of a stem cell research and achievement transformation base in China's reproductive health industry."

The China Reproductive Health Industry Stem Cell Research and Achievement Transformation Base is a joint venture between Shaanxi 38fule Technology Group and Shandong Nuolai Biomedical Technology Co., Ltd. The collaborative base is located in the Shaanxi Yangling 38fule Health Industry Park and the Shandong Tai'an Nuolai International Medical Center, operating in parallel across two parks. The base is established with the aim of meeting the national needs in the frontier areas of life sciences and reproductive health. It focuses on key common technology research, resource development, and the transformation of industrial achievements around fertility reshaping, reproductive health and regulation, stem cells, and regenerative medicine. This initiative serves the national innovation-driven development strategy, aiming to enhance the health level and population quality of the nation.

The joint venture will adhere to the principle of complementary advantages, integrate resources, and construct a comprehensive management system featuring medical consultation, health check-ups, major disease screening, intervention treatment, and health guidance. It will develop and launch high-quality and efficient health products, fully leveraging the link between the regenerative medicine industry and the reproductive health industry. By promoting deep cooperation of high-quality health resources, both parties aim to jointly advance scientific research to support reproductive health and population development.

Yuan, Xiaofeng, a member of the Shaanxi Provincial Committee of the Chinese People's Political Consultative Conference and Chairman of the Shaanxi 38fule Technology Group, stated: Reproductive health is crucial for the population health of our country and affects every individual of childbearing age and every family. With the postponement of childbearing age, environmental pollution, and the trend of serious diseases affecting younger populations, China's reproductive health issues are becoming increasingly severe. Regenerative medicine offers new hope for human health by restoring and replacing the functions of damaged cells, tissues, and organs. Therefore, applying the achievements of regenerative medicine research to the field of reproductive health, to provide protection and promotion for the public's reproductive health, is very meaningful. 38fule views the establishment of this base as an opportunity to strive to be the first in the country to forge a new path that benefits the reproductive health industry with cutting-edge technologies and achievements in regenerative medicine.